Rodgers Brothers Inc. Buys 2,315 Shares of Hologic, Inc. (NASDAQ:HOLX)

Rodgers Brothers Inc. increased its position in Hologic, Inc. (NASDAQ:HOLX) by 2.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 105,096 shares of the medical equipment provider’s stock after purchasing an additional 2,315 shares during the quarter. Hologic makes up 1.0% of Rodgers Brothers Inc.’s holdings, making the stock its 25th largest position. Rodgers Brothers Inc.’s holdings in Hologic were worth $7,576,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. General Partner Inc. acquired a new position in shares of Hologic during the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC raised its position in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC raised its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Finally, Smithfield Trust Co boosted its holdings in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 1.6 %

Shares of Hologic stock opened at $61.32 on Monday. The firm has a market capitalization of $13.76 billion, a PE ratio of 19.34, a P/E/G ratio of 2.14 and a beta of 0.97. The firm’s 50-day moving average price is $65.24 and its 200 day moving average price is $73.24. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on HOLX. Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Evercore ISI dropped their price objective on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Morgan Stanley lowered their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Raymond James reissued an “outperform” rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Hologic presently has an average rating of “Hold” and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.